Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Isofol Medical continued to make solid progress in the third quarter. The ongoing phase Ib/II study of arfolitixorin is advancing according to plan, and the company has now received clearance to escalate to the next dose level following positive safety findings. Meanwhile, partner Solasia Pharma has become one of Isofol’s largest shareholders and is investing SEK 140 million to fund clinical development in Japan. BioStock spoke with CEO Petter Segelman Lindqvist to learn more.
Read the full article at biostock.se:
https://biostock.se/en/2025/11/isofol-nar-nya-milstolpar-i-fas-ib-ii-studien-i-europa-forbereder-japansk-studie-med-solasia/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se